Tempus' PRISM2 AI Model Published in Nature Medicine, Outperforms Peers in Cancer Diagnostics
TEM is trading near its 52-week low of $40.77 (14% above the low).
Summary
Tempus AI's PRISM2, a multimodal pathology foundation model, was published in Nature Medicine and demonstrated best-in-class performance across diagnostic and prognostic tasks, including predicting colorectal cancer recurrence. The model was trained on 2.3 million whole-slide images and 14 million diagnostic question-answer pairs, making it the largest dataset of its kind. This publication validates Tempus' AI capabilities in precision oncology and could accelerate adoption of its platform. The full model weights are publicly available on Hugging Face, supporting open science. The news follows the recent $1.5B Personalis acquisition and strong Q2 results, reinforcing Tempus' position in AI-driven healthcare.
At the time of this announcement, TEM was trading at $46.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3B. The 52-week trading range was $40.77 to $104.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.